(International Diabetes Federation) Eli Lilly & Co. (NYSE:LLY) will investment more than $700 million on insulin production to combat diabetes. Most of the ramp of production will occur in Eli Lilly’s manufacturing facilities in China, France, Puerto Rico, and Indianapolis. Eli Lilly is huge in diabetic drugs, but lately sales within the unit have been suffering from fierce competition from Novo Nordisk A/S (ADR) (NYSE:NVO) line of diabetic drugs. Eli Lilly will invest a large portion of the money in China, which has the largest global population of diabetics according to the International Diabetes Federation. Today is World Diabetes Day, henceforth the news from Eli Lilly.